Beacon Biosignals nabs $27m Series A

Beacon Biosignals, a neurotechnology company, has secured $27 million in Series A financing.

Beacon Biosignals, a neurotechnology company, has secured $27 million in Series A financing. General Catalyst led the round with participation from Casdin Capital.

Source: Press Release